Early risk of cardiovascular events after commencing hormone replacement therapy

Current Opinion in Lipidology

Volumn 12, Issue 4, 2001, Pages 371-375

  Rossouw, Jacques E ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ESTRADIOL; ESTROGEN; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY RISK; FEMALE; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MUTATION; POSTMENOPAUSE; PROGESTINS; PROTHROMBIN; RISK FACTORS;

EID: 0034919319     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200108000-00001     Document Type: Review

References (31)

1. Hormone replacement therapy, heart disease, and other considerations
2. Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the Lipid Research Clinics Program Follow-up Study
3. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
4. Postmenopausal estrogen and progestin and the risk of cardiovascular disease
5. Postmenopausal hormones and recurrence of coronary events in the Nurses' Health Study
6. Early risks of hormone replacement therapy in patients with coronary heart disease
7. Effects of estrogen replacement therapy on the progression of coronary artery atherosclerosis
8. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis
9. Transdermal hormone replacement therapy for the secondary prevention of coronary artery disease in postmenopausal women
10. Estrogen after ischemic stroke: Effect of estrogen replacement on risk of stroke and death in Women's Estrogen for Stroke Trial (WEST)
11. Hormone replacement therapy for secondary prevention of coronary heart disease
12. Estrogen in the prevention of atherosclerosis trial
13. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: Pooled data from clinical trials
14. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women
15. Postmenopausal hormone therapy increases risk of deep vein thrombosis and pulmonary embolism
16. Genetic susceptibility to venous thrombosis
17. Increased risk of deep venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation
18. Thrombotic variables and risk of idiopathic venous thromboembolism in women age 45-64 years
19. Factor V Leiden is not a risk factor for arterial vascular disease in the elderly: Results from the Cardiovascular Health Study
20. Mutation in the gene encoding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men
21. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women
22. Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden mutation (resistance to activated protein C)
23. Hormone replacement therapy, prothrombotic mutations, and the risk of incident myocardial infarction in postmenopausal women
24. A common prothrombin variant (20210 G to A) increased the risk of myocardial infarction in young women
25. Interaction of estrogen replacement therapy with the thrombophilic 20210 G/A prothrombin gene mutation for atherothrombotic vascular disease: A cross-sectional study of 275 hyperlipidemic women
26. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke and venous thrombosis in a large cohort of US men
27. Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management
28. Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women
29. Increased serum matrix metalloproteinase-9 expression in postmenopausal women on estrogen therapy
30. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions